Evidence map›Paper›PMID 42623237›Full record

ArticleSTAR protocols2026

Protocol for detecting cancer in blood using targeted DNA methylation.

Zhaoyu Jiang, Yuqing Guo, Yongqu Lu, Kun Qian, Renjie Luo, Xiaomeng Liu, Jie Ren, Wei Fu, Lu Wen, Xin Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhaoyu JiangDepartment of Gastrointestinal Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan 250000, China; Department of General Surgery, Cancer Center, Biomedical Pioneering Innovation Center, Third Hospital, Peking University, Beijing 100871, China. Electronic address: eternity.7@foxmail.com.
Yuqing GuoDepartment of General Surgery, Cancer Center, Biomedical Pioneering Innovation Center, Third Hospital, Peking University, Beijing 100871, China; Beijing Advanced Innovation Center for Genomics (ICG), Ministry of Education Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing 100871, China.
Yongqu LuDepartment of General Surgery, Cancer Center, Biomedical Pioneering Innovation Center, Third Hospital, Peking University, Beijing 100871, China; Department of Breast and Thyroid Surgery, China-Japan Friendship Hospital, Beijing 100029, China.
Kun QianSchool of Mathematical Sciences and Center for Statistical Science, Peking University, Beijing 100871, China.
Renjie LuoDepartment of General Surgery, Cancer Center, Biomedical Pioneering Innovation Center, Third Hospital, Peking University, Beijing 100871, China; Beijing Advanced Innovation Center for Genomics (ICG), Ministry of Education Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing 100871, China.
Xiaomeng LiuRadiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital &Institute, Chengdu 610041, China.
Jie RenDepartment of General Surgery, Cancer Center, Biomedical Pioneering Innovation Center, Third Hospital, Peking University, Beijing 100871, China; Beijing Advanced Innovation Center for Genomics (ICG), Ministry of Education Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing 100871, China.
Wei FuDepartment of General Surgery, Cancer Center, Biomedical Pioneering Innovation Center, Third Hospital, Peking University, Beijing 100871, China; Beijing Advanced Innovation Center for Genomics (ICG), Ministry of Education Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing 100871, China.
Lu WenDepartment of General Surgery, Cancer Center, Biomedical Pioneering Innovation Center, Third Hospital, Peking University, Beijing 100871, China; Beijing Advanced Innovation Center for Genomics (ICG), Ministry of Education Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing 100871, China. Electronic address: wenlu@pku.edu.cn.
Xin ZhouDepartment of General Surgery, Cancer Center, Biomedical Pioneering Innovation Center, Third Hospital, Peking University, Beijing 100871, China; Beijing Advanced Innovation Center for Genomics (ICG), Ministry of Education Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing 100871, China. Electronic address: zhouxinasd@sina.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we present a protocol for detecting and differentiating colorectal and gastric cancers using plasma cell-free DNA (cfDNA) with targeted methylated CpG tandem amplification and sequencing (tMCTA-seq), a targeted DNA methylation sequencing approach. We describe steps for sample collection, DNA extraction, bisulfite conversion, and targeting 110 methylated sites by coupling locus-specific primers with a universal CGCGCGG primer. We then detail an optional workflow that adapts tMCTA-seq to other cancer types. This approach achieves high sensitivity, below one haploid-genome equivalent, enabling non-invasive cancer detection.

Indexed as

Biotechnology and bioengineeringCancerGene ExpressionGenomicsHealth SciencesMolecular BiologySequencing

Identifiers

PMID42623237
PMCPMC13505419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.